View in EDS

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Saved in:
Bibliographic Details
Title: Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Authors: Curtis NJ; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Mooney L; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Hopcroft L; iMED Oncology, AstraZeneca, Cambridge, UK., Michopoulos F; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Whalley N; iMED Oncology, AstraZeneca, Cambridge, UK., Zhong H; MedImmune, One MedImmune Way, Gaithersburg, MD, USA., Murray C; iMED DSM, AstraZeneca, Cambridge, UK.; C4X Discovery, Manchester, UK., Logie A; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Revill M; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Byth KF; iMED Oncology, AstraZeneca, Gatehouse Park, Waltham, Massachusetts, MA, USA., Benjamin AD; iMED DSM, AstraZeneca, Cambridge, UK., Firth MA; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Green S; iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK., Smith PD; iMED Oncology, AstraZeneca, Cambridge, UK., Critchlow SE; iMED Oncology, AstraZeneca, Cambridge, UK.
Source: Oncotarget [Oncotarget] 2017 May 25; Vol. 8 (41), pp. 69219-69236. Date of Electronic Publication: 2017 May 25 (Print Publication: 2017).
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.18215